Spruce Biosciences financials
$47.27−0.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $697.0K | $602.0K | $1.6M | $2.0M | $2.9M | $3.1M |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $697.0K | $602.0K | $1.6M | $2.0M | $2.9M | $3.1M |
| Gross margin | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$16.5M | -$12.0M | -$11.1M | -$8.2M | -$2.7M | -$14.5M | -$24.1M | -$9.4M | -$10.0M | -$12.6M | -$11.2M | -$13.7M |
| Net income | -$16.2M | -$12.3M | -$14.6M | -$8.2M | -$2.1M | -$14.0M | -$23.6M | -$8.7M | -$9.2M | -$11.6M | -$9.9M | -$12.4M |
| Net margin | — | — | — | — | — | — | −3380.1% | −1440.4% | −570.2% | −580.7% | −344.6% | −402.0% |
| Diluted EPS | $-6.68 | $-8.94 | $-11.04 | $-14.58 | $-3.50 | $-23.95 | $-14.38 | $-15.75 | $-16.73 | $-21.00 | $-18.25 | $-22.50 |
| EBITDA | -$15.9M | -$11.7M | -$11.1M | -$8.2M | -$2.7M | -$14.5M | -$24.1M | -$9.4M | -$10.0M | -$12.6M | -$11.1M | -$13.6M |
| Operating cash flow | -$22.1M | -$8.7M | -$6.5M | -$5.3M | -$8.8M | -$12.7M | -$20.7M | -$9.2M | -$11.1M | -$15.0M | -$11.2M | -$12.3M |
| Free cash flow | -$22.3M | -$8.7M | -$6.5M | -$5.3M | -$8.8M | -$12.7M | -$20.7M | -$9.2M | -$11.1M | -$15.0M | -$11.2M | -$12.3M |
| Diluted shares | 2.4M | 1.4M | 1.3M | 0.6M | 0.6M | 0.6M | 1.6M | 0.6M | 0.5M | 0.5M | 0.5M | 0.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $96.3M | $54.1M | $48.9M | $10.7M | $16.4M | $25.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $7.1M | $6.5M | $0.00 | $539.0K | $943.0K | $1.3M |
| Total assets | $102.9M | $56.2M | $53.0M | $15.3M | $21.8M | $31.6M |
| Total liabilities | $19.1M | $21.5M | $10.5M | $9.9M | $8.6M | $16.3M |
| Shareholders' equity | $83.7M | $34.6M | $42.5M | $5.4M | $13.2M | $15.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology